ArticleJournal of community genetics2025
Universal newborn screening for familial hypercholesterolaemia-insights from healthcare professionals in Queensland, Australia.
Article in Journal of community genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Familial hypercholesterolaemia is a common disorder leading to premature atherosclerotic cardiovascular disease. Despite available treatment options and guideline recommendations for early screening and intervention, fewer than 10% (1 in 10) of individuals with familial hypercholesterolaemia have been identified. Objective To assess if healthcare providers in Queensland, Australia, support introduction of newborn screening for familial hypercholesterolaemia with a focus on benefits, concerns, barriers, and solutions. Methods A survey consisting of 16 items was conducted. Healthcare providers in Endocrinology, Cardiology, Chemical Pathology, Genetic Pathology, Clinical Genetics, General Practice and Genetic Counselling were invited to participate. Results 69 individuals completed the survey. There was strong support for newborn screening for familial hypercholesterolaemia including via genetic testing. Perceived benefits of genetic testing included early diagnosis, prevention of heart disease, reverse cascade screening, robust screening methodology and family planning. Concerns included access to insurance, technical understanding of genetics, parental anxiety, burden to the healthcare system, genetic discrimination, non-paternity, impact on the psychological health of children, child-parent bonding, and delay from diagnosis to initiation of pharmacotherapy during childhood. Main perceived barriers were cost and burden to the healthcare system, lack of a formal consent process and follow-up pathways. A multidisciplinary approach with appropriate funding, education, a formalized consent process and follow-up pathways with local pilot testing were perceived as important steps to overcome these barriers. Conclusion There was widespread support for newborn screening for familial hypercholesterolaemia in a diverse group of healthcare professionals. Further work is required to address concerns and barriers prior to introduction of newborn screening for familial hypercholesterolaemia.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.